Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Therapy in NSCLC Based on ERCC1/RRM1/TS
NCT01781988Phase 2Completed
- Sponsor
- Guangzhou Medical University
- Start
- Jun 2009
- Primary completion
- Dec 2014
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin, gemcitabine and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangzhou Medical University. Primary endpoint: Disease-Free Survival at 4 years. Started Jun 2009; status: completed.
02
Drugs
carboplatingemcitabinepemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01781988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01781988.